MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma

Launched by JIYAN LIU · Jun 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for advanced penile cancer that tests positive for a protein called EGFR. Penile squamous cell carcinoma is a rare and serious type of cancer, and current treatments like chemotherapy often don’t work well enough, especially for advanced stages. This study will look at how well a combination of two medicines—MRG003, which targets the cancer cells directly, and HX008, which helps the immune system fight the cancer—works as the first treatment given to patients with this type of cancer. The goal is to find a treatment that is both effective and causes fewer side effects than current options.

Men who have advanced penile cancer that cannot be removed by surgery and who show EGFR protein on their tumor cells may be eligible to join. Participants must not have had previous treatments for advanced cancer, need to be in generally good health, and have measurable tumors for doctors to track. During the trial, patients will receive the combination treatment and be closely monitored to see how their cancer responds and to watch for any side effects. This study is currently not open for enrollment but aims to offer a new hope for men facing this challenging disease.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically and/or cytologically confirmed unresectable, locally advanced, or metastatic penile squamous cell carcinoma.
• • 2. EGFR expression (defined as IHC 1+, 2+, or 3+) confirmed by the institutional pathology department using primary or metastatic tumor tissue samples.
• • 3. No prior systemic therapy for advanced disease.
• • 4. Male, aged ≥18 years.
• • 5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 with a life expectancy ≥3 months.
• • 6. At least one measurable lesion per RECIST 1.1 criteria.
• 7. Adequate organ function (based on institutional laboratory reference ranges):
• • Left ventricular ejection fraction (LVEF) ≥50%.
• Hematology:
• • Hemoglobin (HGB) ≥90 g/L, White blood cell count (WBC) ≥3.0×10⁹/L, Absolute neutrophil count (ANC) ≥1.5×10⁹/L, Platelet count (PLT) ≥80×10⁹/L.
• Biochemistry:
• • Total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN), AST/ALT ≤2.5×ULN (≤5×ULN if liver metastases present), Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CrCl) ≥50 mL/min.
• • 8. Willing to provide written informed consent, with full understanding of the study requirements and commitment to comply with trial procedures and follow-up visits.
• Exclusion Criteria:
• • 1. Patients who have received prior systemic therapy before enrollment.
• • 2. History of other malignancies, except for cured carcinoma in situ of the cervix, basal cell carcinoma of the skin, or other malignancies that have been disease-free for at least 5 years.
• • 3. Presence of central nervous system metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may be eligible if they have been stable for at least 6 months, show no disease progression on imaging within 4 weeks before treatment, have no neurological symptoms, demonstrate no evidence of new or enlarging brain metastases, and have discontinued radiation, surgery, or steroid therapy for brain metastases at least 28 days prior to the first dose. Carcinomatous meningitis is excluded regardless of clinical stability.
• • 4. Severe or uncontrolled concurrent diseases, including uncontrolled infections, active tuberculosis, uncontrolled diabetes, cardiovascular diseases (such as NYHA Class III or IV heart failure, second-degree or higher heart block, myocardial infarction within the past 12 months, unstable arrhythmia or angina, or cerebral infarction within the past 6 months), pulmonary diseases (such as interstitial lung disease, chronic obstructive pulmonary disease, or a history of symptomatic bronchospasm), deep vein thrombosis or pulmonary embolism within the past 12 months, or decompensated cirrhosis.
• • 5. Active autoimmune disease requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within the past 2 years. Replacement therapies (e.g., thyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary insufficiency) are permitted.
• • 6. Positive serological virology test results, including HIV positivity, HBsAg positivity with detectable HBV DNA (≥2000 copies/mL), or HCV antibody positivity (eligible only if HCV RNA PCR-negative).
• • 7. Major surgery within 4 weeks before enrollment, or prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation.
• • 8. Administration of or plans to receive anti-cancer vaccines within 4 weeks before enrollment or during the study.
• • 9. Clinically significant pleural effusion or ascites, as determined by the investigator to be unsuitable for enrollment.
• • 10. Any other condition considered by the investigator to make the patient ineligible for the clinical study.